Buy this Article for $10.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Keywords

advanced heart failure, mechanical circulatory support, symptom biochemistry, ventricular assist device

 

Authors

  1. Lee, Christopher S. PhD, RN, FAHA
  2. Mudd, James O. MD
  3. Gelow, Jill M. MD, MPH
  4. Nguyen, Thuan MD, PhD
  5. Hiatt, Shirin O. MPH, MS, RN
  6. Green, Jennifer K. MS
  7. Denfeld, Quin E. BSN, RN, CCRN
  8. Bidwell, Julie T. BSN, RN
  9. Grady, Kathleen L. PhD, APN, FAHA, FAAN

Abstract

Background: Unexplained heterogeneity in response to ventricular assist device (VAD) implantation for the management of advanced heart failure impedes our ability to predict favorable outcomes, provide adequate patient and family education, and personalize monitoring and symptom management strategies. The purpose of this article was to describe the background and the design of a study entitled "Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure" (PREMISE).

 

Study Design and Methods: PREMISE is a prospective cohort study designed to (1) identify common and distinct trajectories of change in physical and psychological symptom burden; (2) characterize common trajectories of change in serum biomarkers of myocardial stress, systemic inflammation, and endothelial dysfunction; and (3) quantify associations between symptoms and biomarkers of pathogenesis in adults undergoing VAD implantation. Latent growth mixture modeling, including parallel process and cross-classification modeling, will be used to address the study aims and will entail identifying trajectories, quantifying associations between trajectories and both clinical and quality-of-life outcomes, and identifying predictors of favorable symptom and biomarker responses to VAD implantation.

 

Conclusions: Research findings from the PREMISE study will be used to enhance shared patient and provider decision making and to shape a much-needed new breed of interventions and clinical management strategies that are tailored to differential symptom and pathogenic responses to VAD implantation.